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Alcohol dependence is associated with a dysregulated dopamine system modulating reward,
craving and cognition. The monoamine stabilizer (-)-OSU6162 (OSU6162) can counteract both
hyper- and hypo-dopaminergic states and we recently demonstrated that it attenuates
alcohol-mediated behaviors in long-term drinking rats. The present Phase II exploratory
human laboratory study investigated to our knowledge for the ﬁrst time the effects of
OSU6162 on cue- and priming-induced craving in alcohol dependent individuals. Fifty-six
alcohol dependent individuals were randomized to a 14-day-treatment period of OSU6162 or
placebo after their baseline impulsivity levels had been determined using the Stop Signal
Task. On Day 15, participants were subjected to a laboratory alcohol craving test comprised
of craving sessions induced by: i) active – alcohol speciﬁc cues, ii) neutral stimuli and iii)
priming – intake of an alcoholic beverage (0.20 g ethanol/kg bodyweight). Subjective ratings
of alcohol craving were assessed using the shortened version of the Desire for Alcohol
Questionnaire and visual analog scales (VAS). OSU6162 treatment had no signiﬁcant effect on
cue-induced alcohol craving, but signiﬁcantly attenuated priming-induced craving. Explora-
tory analysis revealed that this effect was driven by the individuals with high baseline
impulsivity. In addition, OSU6162 signiﬁcantly blunted the subjective liking of the consumed
alcohol (VAS). Although the present 14-day-treatment period, showed that OSU6162 was safe
and well tolerated, this exploratory human laboratory study was not designed to evaluate theo.2015.09.018
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2241Effects of OSU6162 on Craving for Alcoholefﬁcacy of OSU6162 to affect alcohol consumption. Thus a larger placebo-controlled
efﬁcacyclinical trial is needed to further investigate the potential of OSU6162 as a novel
medication for alcohol dependence.
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The mesolimbic dopamine system is a well-studied neuro-
biological system in the development and maintenance of
drug and alcohol dependence. The acute reinforcing effects
of addictive drugs, including alcohol, is mediated in part by
increased dopamine release in the nucleus accumbens
(Boileau et al., 2003; Di Chiara and Imperato, 1988;
Imperato and Di Chiara, 1986), activating dopamine D2
receptors (Nowak et al., 2000). In alcohol dependent
individuals, brain-imaging studies using positron emission
tomography (PET) have revealed a reduction of availability
of dopamine D2-receptors suggested to reﬂect a compensa-
tory down-regulation induced by chronic alcohol intake
which has also been associated with a subsequent risk for
relapse (Heinz et al., 2009, 2005; Volkow et al., 1996). In
addition, the dopamine dysfunction observed in the human
studies was correlated with the severity of alcohol craving
as well as an increased activation in brain striatal regions
when exposed to alcohol-related cues, reﬂecting an atten-
tional bias to the speciﬁc cues and risk for relapse (Heinz
et al., 2004). Furthermore, it was recently demonstrated
that alcohol dependent individuals have decreased dopa-
mine levels also in the prefrontal cortex (Narendran et al.,
2014), suggesting that cortical dopamine deﬁcits may con-
tribute to the cognitive impairments (e.g. reduced impulse
control and attention) seen in alcohol dependent individuals
(Goldstein and Volkow, 2011; Stavro et al., 2013). In fact,
recent studies have investigated the implications of the
neural links relating to the change in the dopamine system
and impulsive behaviors, to understand their putative
relevance in alcohol dependence. The results indicate an
association between alcohol use, increased impulsivity, an
elevated subjective response to alcohol (Leeman et al.,
2014) and increased dopamine levels (Boileau et al., 2003),
suggesting that impulsivity (Dick et al., 2010) and the
subjective response to alcohol (Crabbe et al., 2010) are
risk factors for alcohol dependence.
The dopamine system has previously been evaluated as a
potential treatment target for alcohol dependence, how-
ever, studies with traditional dopamine antagonists and
agonists have been discouraging (Swift, 2010). The use of
dopamine antagonists (i.e. neuroleptics) is further limited
by severe side effects including anhedonia and extrapyr-
amidal reactions resulting from excessive dopaminergic
inhibition. However, recently modaﬁnil (a dopamine trans-
porter modulator) and aripiprazole (a commercial com-
pound conceptually developed from the partial D2-agonist
(-)-3PPP (Carlsson and Carlsson, 2006)) has been shown to
decrease alcohol intake and craving in alcohol dependent
individuals (Joos et al., 2013; Martinotti et al., 2009, 2007;
Myrick et al., 2010; Schmaal et al., 2013; Voronin et al.,
2008). These results indicate that dopamine agents withoutcomplete antagonism or agonism hold promise for efﬁca-
cious treatment of alcohol dependence.
The monoamine stabilizer (-)-OSU6162 (OSU6162)
(Carlsson et al., 2004; Sonesson et al., 1994), is a further
development from (-)-3PPP with the ability to stimulate,
suppress or show no effect on the dopamine activity
depending on the prevailing dopaminergic tone. This
concept was postulated based on a PET study in rhesus
monkeys where OSU6162-infusions induced a dopaminergic
tone-dependent effect with a reduction in the striatal L-
[11C]DOPA inﬂux rate in monkeys with high baseline values
and an increased striatal L-[11C]DOPA inﬂux rate in animals
with low baseline values (Tedroff et al., 1998). The
mechanism of action is however not completely under-
stood, and although in vitro studies indicate that OSU6162,
like aripiprazole, acts as a partial agonist at D2-receptors
(Kara et al., 2010; Seeman and Guan, 2007), behavioral
studies have failed to demonstrate any intrinsic activity of
the compound (Natesan et al., 2006; Sonesson et al.,
1994). Instead it has been suggested that OSU6162 pro-
duces functionally opposite effects by acting as an antago-
nist at both presynaptic autoreceptors and postsynaptic D2
receptors (Carlsson et al., 2004; Lahti et al., 2007; Rung
et al., 2008; Sonesson et al., 1994). Furthermore, OSU6162
appears to be clinically safe with side effects of mild
severity in healthy volunteers (Rodríguez et al., 2004) and
patients with e.g. Huntingtons disease and mental fatigue
following stroke and brain trauma (Johansson et al., 2012;
Kloberg et al., 2014; Tedroff et al., 1999). Thus an
advantage of OSU6162 compared to traditional D2 antago-
nists, might be the lack of extrapyramidal reactions
(Carlsson and Carlsson, 2006).
We recently identiﬁed OSU612 as a potential novel
medication for alcohol dependence by showing that it
attenuates voluntary alcohol consumption, alcohol seek-
ing, withdrawal and cue/priming-induced reinstatement of
alcohol seeking in long-term drinking rats (Steensland
et al., 2012). Furthermore, OSU6162’s potential to target
the dopamine system in brain regions relevant for alcohol
dependence is supported by a recent human PET study
showing that OSU6162 preferentially binds to D2/D3-
receptors in the striatum (Tolboom et al., 2015) and our
recent microdialysis study showing that the compound can
counteract a hypodopaminergic state in long-term drinking
rats (Feltmann, et al., 2015). Based on these results, the
present study evaluated the effects of OSU6162 on cue-
and priming-induced craving in alcohol dependent indivi-
duals in a Phase II placebo-controlled human laboratory
study. Based on the growing body of research indicating a
signiﬁcant neurobiological overlap between impulsivity
and alcohol dependence (Dick et al., 2010; Lejuez et al.,
2010) and the knowledge that impulsivity is an important
predictor of treatment outcome (Joos et al., 2013;
L. Khemiri et al.2242Schmaal et al., 2013; Voronin et al., 2008) we also
investigated whether baseline impulsivity predicted treat-
ment response to OSU6162.
2. Experimental procedures
2.1. Participants
Fifty-six treatment-seeking alcohol dependent individuals
were recruited through public advertisements. The study
physician provided verbal and written information about the
procedures, before seeking participants’ written informed
consent. Individuals who completed the study and the
follow-up visit were compensated with 1500 Swedish Crowns
(approximately 180 USD). The study was approved by the
regional ethical review board in Stockholm and the Swedish
Medical Products Agency, registered in the European Clinical
Trials Database (EudraCT;2011-003133-34), monitored by
Karolinska Trial Alliance and conducted in accordance with
Good Clinical Practice and the Declaration of Helsinki.
After a brief telephone interview, potential participants
were invited to the Stockholm Center for Dependency
Disorders outpatient research clinic, Karolinska University
Hospital (KUH) for a screening visit consisting of physical
examination, psychiatric evaluation, blood samples, breath-
alyzer, urine test and electrocardiogram (ECG, Mortara
Instrument ELI150c). In brief, included individuals were
between 20 and 55 years old, fulﬁlling the DSM-IV criteria
for alcohol dependence, had at least 45 heavy drinking days
(HDD; deﬁned as a day with consumption of at least 5 or
4 standard drinks (deﬁned as 12 g alcohol per drink) for men
and women, respectively) within the last 90 calendar days
from inclusion and had not consumed alcohol for a minimum
of four, and a maximum of 14 days before inclusion, conﬁrmed
by Time Line Follow Back (TLFB) interview (Sobell and Sobell,
1992) and breathalyzer. In brief, exclusion criteria’s were
fulﬁllment of DSM-IV criteria for any other type of substance
use disorder (except nicotine), DSM-IV criteria for schizo-
phrenia, bipolar disorder, major depression or presence of any
previous heart disease of clinically signiﬁcant ECG abnormal-
ities. The complete inclusion and exclusion criteria are
provided in Supplementary Information (SI).
2.2. Study design
In this double blind, placebo-controlled study, participants
were randomized to receive OSU6162 or matched placebo
tablets (Galenica AB, Malmö, Sweden) during a 14-day-
treatment-period and were instructed to take medication
according to the following schedule: Day 1–5:10 mg 2; Day
6–10:15 mg 2; Day 11–14:30 mg 2. The length of the
treatment period was based on a recommendation from
Swedish Medical Products Agency as the present study was
the ﬁrst to evaluate OSU6162 in an alcohol dependent
population. The randomization procedure (see SI for details)
was done by the Karolinska Trial Alliance, without the
involvement of the research staff and the medication was
dispensed to the research clinic by the KUH pharmacy. The
study comprised three follow-up visits during the 14-day-
treatment-period and a laboratory based alcohol craving
test session on day 15 (Test day). The follow-up visitsincluded ECG, blood and urine sample collection, medica-
tion dispensing, breathalyzer test and reporting of drinking,
mood, and adverse events. Participants were instructed to
refrain from drinking during the treatment period, although
drinking was not ground for exclusion. However, alcohol
intake the day before and on the Test day (conﬁrmed via
TLFB and breathalyzer) resulted in exclusion from the
craving test session to prevent bias in the subjective craving
experience.
On the Test day participants arrived at the research clinic
in the morning, and took the ﬁnal dose of study medication
in the presence of a research staff. Nicotine and caffeine
was allowed before arrival, but not during the course of the
Test day. After completion of the craving experimental
sessions, participants received lunch and debrieﬁng and
stayed in the research clinic until they were sober. All
participants were offered referral for treatment within the
Stockholm Center for Dependency Disorders.
2.3. Alcohol craving test sessions
The human laboratory test sessions were modiﬁed from
(Hammarberg et al., 2009), and the procedures are
described in detail in SI. In brief, the test comprised three
craving sessions induced by: i) active – alcohol speciﬁc cues,
ii) neutral stimuli and iii) priming – intake of an alcoholic
beverage (0.20 g ethanol/kg bodyweight).
The order of the cue sessions (active cue and neutral
stimuli) was randomized and counter-balanced between
participants, within each treatment group. During each
session, subjective ratings of alcohol craving were collected
before, immediately after and at 5 and 10 min post cue
presentation (the mean of the two latter time-points was
deﬁned as “post-cue” measurements). Craving was assessed
using the shortened Swedish version of the Desire for Alcohol
Questionnaire (Short-DAQ) (Love et al., 1998) consisting of
eight items (Table S1) scored on a seven-point Likert scale
where 1 and 7 indicated “Do not agree at all” and “Fully
agree”, respectively, as well as a single-item Visual Analog
Scale (VAS, ranging from 0 to 100) measuring “How much
craving for alcohol do you experience right now?”.
Post the cue sessions, the priming session was conducted
during which each participant ﬁrst took one sip of their
preferred alcoholic beverage before ﬁnishing the drink.
Subjective craving ratings were collected: before, immedi-
ately after, as well as 5, 10, 25 and 40 min after ﬁnishing the
alcoholic beverage (the mean of the four latter time-points
were deﬁned as “post-drink” measurements) and assessed
with Short-DAQ and VAS as described above. To capture
subjective effects immediately after the ﬁrst sip of alcohol,
VAS items of “craving”, “anxiety” and “arousal” were col-
lected. In addition, a VAS item of “liking” was included as an
amendment to the protocol after the ﬁrst 15 participants.
2.4. Clinical measures
Psychiatric evaluation was done at screening using the
Structured Clinical Interview for DSM-IV (American
Psychiatric Association, 2000). Mood and craving during
treatment were assessed using the Montgomery-Åsberg
Depression Self Rating Scale (MADRS-S) (Svanborg and
2243Effects of OSU6162 on Craving for AlcoholAsberg, 2001) and the Penn Alcohol Craving Scale (PACS)
(Flannery et al., 1999), respectively. Alcohol consumption
was quantiﬁed as change between inclusion and Test day in
percent HDD (TLFB self-report) and phosphatidylethanol
(PEth) serum levels (analyzed by the clinical chemistry
laboratory, KUH). Presence of illicit drugs e.g., ampheta-
mine, cocaine, cannabis (THC) or opiates was evaluated on
weekly follow-up visits using urine dipsticks. Veriﬁcation of
positive samples was conducted at the aforementioned
laboratory. OSU6162 compliance was measured by plasma
concentrations (analysis methodology in SI) on second
follow-up visit and Test Day, and pill counts on every visit.
ECG was recorded and evaluated by a cardiologist as a
safety measure at the second follow-up visit and Test day.
2.5. Behavioral task of impulsivity
During the inclusion visit (before intake of study medica-
tion), participants performed the Stop Signal Task (SST, see
SI for methodological details), a computerized neuropsy-
chological test widely used as a measure of impulsivity
(Aron et al., 2003; DeVito et al., 2009). The outcome of
interest was the stop signal reaction time (SSRT)-a measure
of the participants’ ability to inhibit a prepotent response.
Each participant was deﬁned as being high or low impulsive,
based on the median split of the SSRT scores in accordance
with previous studies in alcohol dependent individuals (Joos
et al., 2013; Schmaal et al., 2013).
2.6. Statistical analysis
The primary outcomes were (i) total Short-DAQ and (ii) VAS
scores, respectively, for craving during the laboratory test
sessions. Data were analyzed using mixed ANOVAs with
Treatment (OSU6162 or placebo) as between-subject factor.
Within-subject factors were Condition (active, neutral) and
Time (before, immediately after and post-cue) for the cue-
induced sessions and Time (before, immediately after and
post-drink) for the priming-induced session. Signiﬁcant mainTable 1 Participant characteristics at inclusion. There were n
treated groups for any of the outcomes. Continuous variables a
MADRS-S-Montgomery-Åsberg Depression Self Rating Scale; PACS
OSU6162 (n
Males/Females 14/14
Age 47.3(6.5)
Education years 13.3(2.5)
Married/Partner 54%
Full time employment 78.6%
Part time employment 7.1%
Unemployed 14.3%
Sick leave/retired 0%
Daily nicotine use(%) 68%
DSM-IV criteria for alcohol dependence 5.2(1.1)
Heavy drinking last 90 days (%) 73%
Drinks per day last 90 days 5.8(2.2)
MADRS-S score 9.2(6.8)
PACS craving score 11.1(6.5)effect of Treatment or Condition and interactions were
further analyzed using Student's unpaired or paired t-tests,
where appropriate. Data from the VAS items after the ﬁrst
alcohol sip (priming-session) were analyzed by separate
Student’s unpaired t-tests, comparing scores between treat-
ment groups.
In a priori determined exploratory analyzes, separate
ANOVAs were performed to evaluate the potential inﬂuence
of baseline impulsivity (i.e. high or low impulsive based on
median split of the SSRT (Joos et al., 2013; Schmaal et al.,
2013)), on the outcome from the cue- and priming-induced
craving test sessions, respectively. Difference in alcohol
consumption (HDD and Peth), craving (PACS) and mood
(MADRS-S) between inclusion and Test day were compared
between treatment groups using Student’s unpaired t-tests.
This human laboratory study is to our knowledge the ﬁrst
exploratory study evaluating the effects of OSU6162 in
alcohol dependent patients, using two different but highly
dependent measurements of subjective craving. Thus, the
risk of type 1 error was deemed less troublesome than type
2 errors, and the alpha-level was set to 0.05, two-tailed,
uncorrected. Data was assessed for normality by ocular
inspection together with Shapiro Wilks normality test and
analyzed using IBM SPSS statistics (version 21.0, SPSS inc.,
Chicago, Illinois). If equality of variances was violated
(assessed by Levenes test), the results of the Welch t-test
were reported. Greenhouse-Geisser corrections were
applied if the sphericity assumption was violated (evaluated
using Mauchlys test). Missing values were not replaced. If
not stated otherwise, mean values7standard deviations are
reported.
3. Results
3.1. Participants
Study recruitment began in September 2012, and the last
participant visit was in December 2013. The two treatment
groups were homogeneous at inclusion with regards too signiﬁcant differences between the OSU6162- or placebo-
re presented as mean (standard deviation). Abbreviations:
-Penn Alcohol Craving Scale.
=28) PLACEBO (n=28) Signiﬁcance
16/12 p=0.60
45.3(7.7) p=0.30
14.1(2.8) p=0.26
54% P=1.0
71.4% P=0.54
17.9% P=0.23
7.1% P=0.39
3.6% P=0.31
64% P=1.0
5.1(1.4) P=0.62
68% P=0.29
5.7(2.4) P=0.88
7.9(6.7) P=0.46
10.4(6.0) P=0.70
L. Khemiri et al.2244sociodemographic background, alcohol consumption patterns,
craving and mood (Table 1). Of the 56 randomized, one
participant in the placebo group dropped out after a severe
relapse on Day 1. Thus, 55 participants completed the 14-day-
treatment-period and provided data regarding alcohol use,
craving, mood and side effects. Seven participants were
excluded from the alcohol craving test sessions because of:
alcohol consumption the day before (n=3), not complying
with study procedures during Test day (n=1) or presenting
urine sample positive for opiates (n=2) or THC (n=1). In the
priming session, three participants did not comply with study
procedures after taking the ﬁrst sip of alcohol, and thus only
provided data for the baseline and ﬁrst sip time-points. In the
OSU6162 group, analyzed blood samples had detectable
OSU6162 plasma levels on Day 7 (38.9724.7 ng/mL) and the
Test day (105.0773.8 ng/mL). No OSU6162 was detected at
any time-point in any blood samples from the placebo group.3.2. OSU6162 did not attenuate subjective ratings
of cue-induced craving
In the cue-induced craving sessions (Short-DAQ; Figure 1),
there was a signiﬁcant main effect of Condition (F(1,45)
=76.5;po0.001) and Time (F(2,90)=21.1;po0.001) but no
signiﬁcant main effect of Treatment (F(1,45)=2.1;p=0.154).
In addition, there was a signiﬁcant Time*Condition interaction
(F(1.7,76.2)=22.5;po0.001) but no signiﬁcant Treatment*-
Condition (F(1,45)=1.3;p=0.262) or Time*Condition*Treat-
ment interaction (F(2,90)=1.1;p=0.320). Thus, based on the
lack of signiﬁcant treatment effects, post hoc analyzes were
conducted to evaluate differences between the active and
neutral sessions regardless of treatment. There was a sig-
niﬁcantly higher level of subjective craving immediately afterNeutral Cue 
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Figure 1 The monoamine stabilizer OSU6162 did not attenuate s
patients. Mean craving total scores on the shortened version of
(A) neutral and (B) active cue-induced craving session. There was
OSU6162- and placebo-treated groups during the neutral or active
time-points: before, immediately after and at 5 and 10 min post c
deﬁned as “post-cue” measurements). Values are presented as mepresentation of the active cue (24.078.6) compared to the
neutral stimuli (17.378.9;t(46)=8.0;po0.001) as well as
compared to before (18.979.2;t(46)=6.0;po0.001) and
post presentation of the active cue (19.879.3;t(46)=5.7;
po0.001). Within the neutral condition, there was no sig-
niﬁcant difference in the level of subjective craving between
any of the measured time-points (Before:17.878.8; Immedi-
ately after:17.378.9 and Post:17.178.8). The VAS craving
data yielded signiﬁcant effects on cue-craving (Figure S1)
similar to the Short-DAQ results (see SI for full analysis).3.3. OSU6162 attenuated subjective ratings of
priming-induced craving
During the priming-induced craving session, the mean time
to ﬁnish the alcoholic beverage was 8.6 min (ranging from
three to 18 min between subjects) with no signiﬁcant
difference between treatment groups (t(42)=0.09;
p=0.927). When analyzing the Short DAQ data there was a
signiﬁcant main effect of Time (F(1.5,63.6)=13.7;po0.001)
and Treatment (F(1,43)=4.1;p=0.050) but no signiﬁcant
Time*Treatment interaction (F(1.5,63.6)=1.4;p=0.255).
Post hoc analysis revealed that the OSU6162-treated indivi-
duals had signiﬁcantly lower levels of subjective craving
compared to placebo immediately after ﬁnishing the alco-
holic drink. However, no signiﬁcant difference was found
between the different treatment groups before or post
ﬁnishing the drink (mean of time-points 5, 10, 25 and
40 min; Figure 2A). For the VAS data (Figure 2B) there was
a signiﬁcant main effect of Time (F(1.6,70,2)=29,2;
po0.001) and a trend toward signiﬁcance for Treatment
(F(1,43)=3.3;p=0.075) but no signiﬁcant Time*Treatment
interaction (F(1.6, 70,2)=0.85;p=0.412).Active Cue 
0
5
10
15
20
25
30
35
40
S
ho
rt-
D
A
Q
 (t
ot
al
 s
co
re
)
Placebo
(-)-OSU6162
Before Immediately
After
Post
g Sessions
ubjective ratings of cue-induced craving in alcohol dependent
the Desire for Alcohol Questionnaire (Short-DAQ) during the
no statistically signiﬁcant difference in craving between the
cue sessions, respectively. Data was collected at the following
ue presentation (the mean of the two latter time-points were
an7s.e.m.
Priming-Induced Craving Session
0
5
10
15
20
25
30
35
40
S
ho
rt-
D
A
Q
 (t
ot
al
 s
co
re
)
Placebo
(-)-OSU6162
*
Before Immediately
After
Post
Short-DAQ
0
5
10
15
20
25
30
35
40
45
50
V
A
S
 s
co
re
Placebo
(-)-OSU6162
*
Before Immediately
After
Post
VAS After First Sip of Alcohol
Craving Liking Anxiety Arousal
0
10
20
30
40
50
60
70
80
V
A
S
  s
co
re
*
Placebo
(-)-OSU6162
Figure 2 The monoamine stabilizer OSU6162 attenuated subjective ratings of priming-induced craving in alcohol dependent
patients. Mean total scores on (A) the shortened version of the Desire for Alcohol Questionnaire (Short-DAQ) and (B) VAS craving item
during the priming-induced craving session as well as (C) VAS-items of “craving”, “liking”, “anxiety” and “arousal” after the ﬁrst sip
of alcohol. The OSU6162-treated group rated signiﬁcantly lower craving (Short-DAQ) immediately after ﬁnishing the alcoholic drink
compared to the placebo-treated group (A) and there was a trend towards decreased craving in the OSU6162- compared to the
placebo-treated group using the VAS at the same time-point (B). The OSU6162 group further rated signiﬁcantly lower subjective
liking, and a trend toward lower craving, after the ﬁrst sip of alcohol (C). Data was collected at the following time-points: before
drink, after the ﬁrst sip, immediately after ﬁnishing the alcoholic beverage, as well as 5, 10, 25 and 40 min post consumption of the
alcoholic beverage (the mean of the four latter time-points were deﬁned as “post-drink” measurements). Values are presented as
mean7s.e.m; *po0.05 compared to corresponding placebo.
2245Effects of OSU6162 on Craving for AlcoholAfter the ﬁrst sip from the alcoholic beverage (Figure 2C),
OSU6162 treated individuals reported signiﬁcantly lower
subjective liking of the alcohol (t(31)=2.27;p=0.031) and
a trend toward lower craving (t(46)=1.88;p=0.066) com-
pared to placebo, while there was no signiﬁcant difference
between treatment groups regarding arousal (t(46)=1.29;
p=0.205) or anxiety (t(46)=0.24;p=0.814).3.4. The ability of OSU6162 to attenuate alcohol
craving was driven by individuals with high baseline
impulsivity
In individuals with high baseline impulsivity, the analysis of
the Short-DAQ data from the cue-induced craving sessions
revealed a signiﬁcant main effect of Treatment (F(1,22)
=4.5;p=0.044), but no signiﬁcant Treatment*Condition
interaction (F(1,22)=1.4;p=0.248) or Time*Condition*-
Treatment interaction (F(1.5,32.2)=0.93;p=0.377). Post
hoc analysis revealed that the high impulsive OSU6162-
treated individuals rated signiﬁcantly lower subjective
craving immediately after, and post (mean of the 5 and
10 min time-points) the presentation of the neutral cue
compared to placebo-treated individuals (Figure 3A, left
panel). In the active cue session, there was a signiﬁcant
decrease in subjective craving in the OSU6162-, compared
to placebo-treated individuals only post presentation of the
active cue (Figure 3A, right panel). In individuals with low
baseline impulsivity, however, there was no signiﬁcant main
effect of Treatment (F(1,21)=0.16;p=0.695), and no sig-
niﬁcant Treatment*Condition (F(1,21)=0.152;p=0.701) orTime*Condition*Treatment (F(2,42)=0.275;p=0.761) inter-
actions (Figure 3B). The VAS data yielded signiﬁcant
effects on cue-induced craving in high and low impulsive
individuals similar to the Short-DAQ results (see details in SI;
Figure S2).
In the priming-induced craving session, analysis of the
Short-DAQ data from individuals with high baseline impul-
sivity showed a signiﬁcant main effect of Treatment (F
(1,20)=9.8;p=0.005) and Time (F(1.3,26.0)=8.8;p=0.004)
but no signiﬁcant Time*Treatment interaction (F(1.3,26.0)
=2.5;p=0.116). Post hoc analysis revealed that the
OSU6162 group had signiﬁcantly lower subjective craving
than the placebo group at all measured time-points
(Figure 4A, left panel). In contrast, in individuals with low
baseline impulsivity (Figure 4B, left panel), there was a
main effect of Time (F(2,42)=4.3;p=0.021) but no signiﬁ-
cant main effect of Treatment (F(1,21)=0.12;p=0.731) or
Time*Treatment interaction (F(2,42)=0.428;p=0.639). The
VAS data yielded signiﬁcant effects on priming-induced
craving in high and low impulsive individuals similar to the
Short-DAQ results (Figure 4A and B, middle panels; See SI for
full statistical analysis).
After the ﬁrst sip of alcohol, the OSU6162-treated
individuals with high, but not low, baseline impulsivity rated
signiﬁcantly lower on the VAS craving item compared to
placebo (High:t(22)=2.9, Figure 4A, right panel; Low:t(22)
=0.45, Figure 4B, right panel). There was no signiﬁcant
difference between the treatment groups in any of the
other VAS item assessed after the ﬁrst sip of alcohol in
neither the high nor the low impulsive individuals (Figure 4A
and B, right panels).
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Figure 3 The monoamine stabilizer OSU6162 attenuated cue-induced craving in alcohol dependent individuals with high baseline
impulsivity. Mean craving total scores on the shortened version of the Desire for Alcohol Questionnaire (Short-DAQ) in (A) high and
(B) low impulsive alcohol dependent individuals during cue-induced craving sessions. (A) OSU6162 signiﬁcantly reduced craving in
the high impulsive alcohol dependent individuals compared to placebo immediately after, and post presentation of the neutral cue,
as well as post presentation of the alcoholic cue presentation. (B) No difference in craving was found between OSU6162 and placebo
group in the low impulsive alcohol dependent individuals. Data was collected at the following time-points: before, immediately
after and at 5 and 10 min post cue presentation (the mean of the two latter time-points were deﬁned as “post-cue” measurements).
Values are presented as mean7s.e.m; *po0.05 compared to corresponding placebo.
L. Khemiri et al.22463.5. OSU6162 had no signiﬁcant effect on
drinking, craving or mood during treatment
During the 14-day-treatment-period, the OSU6162 group
signiﬁcantly reduced their drinking from 73 to 19 percent
HDD (t(27)=9.9;po0.001) paralleled by a signiﬁcant reduc-
tion in serum PEth levels from 0.83 to 0.60 (t(27)=2.7;
p=0.012). The placebo group signiﬁcant reduced their
drinking from 68 to 10 percent HDD (t(26)=15.9;po0.001)
and from 0.69 to 0.54 in serum PEth levels (t(26)=2.5;
p=0.020). However, there were no statistically signiﬁcant
difference between treatment groups regarding change in
percent HDD (OSU6162:54.670.29; Placebo:57.670.19;
t(46.4)=0.45;p=0.658), serum PEth levels (OSU6162:0.2370.45; Placebo:0.1570.31; t(48.4)=0.77;p=
0.447), PACS score (OSU6162:4.9; Placebo:4.2; t(53)
=0.541;p=0.591) or MADRS-S score (OSU6162:3.6;
Placebo:2.9; t(53)=0.641;p=0.524) during the treat-
ment period. Finally, there were no signiﬁcant treatment
effects on any drinking, craving or mood outcomes during the
treatment period when the participants were divided into
high- and low-impulsive individuals (See SI for statistical
details).
3.6. Side effects
The OSU6162 treatment was generally well tolerated with-
out any reports of serious side effects and no signiﬁcant
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Figure 4 The monoamine stabilizer OSU6162’s ability to attenuate priming-induced craving in alcohol dependent individuals was
driven by the individuals with high baseline impulsivity. Mean craving total score on the shortened version of the Desire for Alcohol
Questionnaire (short-DAQ) and VAS craving item in (A) high and (B) low impulsive alcohol dependent individuals during the priming-
induced craving session. (A) OSU6162 signiﬁcantly reduced craving in the high impulsive alcohol dependent individuals compared to
placebo during the priming-induced craving session, including craving after the ﬁrst sip of alcohol (right panel). (B) No signiﬁcant
difference in craving was found at any time-point between the OSU6162- and placebo-treated group in the low impulsive alcohol
dependent individuals. Data was collected at the following time-points: before drink, after the ﬁrst sip, immediately after ﬁnishing
the alcoholic beverage, as well as 5, 10, 25 and 40 min post consumption of the alcoholic beverage (the mean of the four latter time-
points were deﬁned as “post-drink” measurements).Values are presented as mean7s.e.m; *po0.05 and **po0.01 compared to
corresponding placebo.
2247Effects of OSU6162 on Craving for Alcoholdifference in the frequency of side effect reports (e.g.
headaches, gastrointestinal symptoms, fatigue and vertigo)
compared to the placebo group (Table S2). Comparison of
ECG at screening compared to test day showed that the
OSU6162 group had signiﬁcantly greater decrease in heart
rate compared to the placebo group (OSU6162:7.6;
Placebo:0.15; t(52)=2.6; p=0.013). No signiﬁcant dif-
ference in QTc changes was found between the treatment
groups (OSU6162:1.8 ms; Placebo:3.9 ms; t(48)=0.32;
p=0.752).
4. Discussion
The present human laboratory study is, to our knowledge,
the ﬁrst evaluation of the monoamine stabilizer OSU6162’seffect on clinically relevant alcohol use outcomes, such as
craving, in alcohol dependent individuals. The main ﬁndings
were that OSU6162, compared to placebo, signiﬁcantly
attenuated subjective ‘liking’ of the consumed alcohol and
priming-induced craving, an effect driven by individuals with
high levels of baseline impulsivity. Together with our previous
results showing that OSU6162 attenuates alcohol-mediated
behaviors in long-term drinking rats (Steensland et al., 2012),
the present results indicate that pharmacological stabiliza-
tion of the dopamine system might prove useful in modulat-
ing some of the reward driven behaviors in alcohol
dependence and that OSU6162 might have potential as a
novel medication for alcohol dependence.
OSU6162 had no signiﬁcant effect on cue-induced alcohol
craving, but signiﬁcantly blunted priming-induced craving in
L. Khemiri et al.2248dependent individuals. The lack of treatment effect on cue-
induced craving could possibly be explained by the methodo-
logical challenges that subjective cue-craving response for
alcohol is less robust than for other drugs of abuse (Lingford-
Hughes et al., 2006). A signiﬁcant decrease in subjective
priming-induced craving as assessed by Short-DAQ was indeed
observed following OSU6162 treatment compared to placebo,
immediately after the participants had ﬁnished the alcoholic
beverage. However, it should be noted that when the craving
was assessed using a VAS, there was no signiﬁcant effect
(although a trend). The ﬁndings that OSU6162 blunted
priming-induced craving as well as the liking of alcohol
indicate that the dopamine stabilizing properties of this agent
are evident when alcohol is consumed.
The mechanism behind OSU6162’s ability to attenuate
alcohol-mediated behaviors in rodents (Steensland et al.,
2012) and alcohol dependent individuals as presented in the
current study is at present, not fully understood. It is possible
that OSU6162 caused a general emotional blunting in a
nonspeciﬁc manner. However, this is unlikely since OSU6162
had no signiﬁcant effect on anxiety or arousal. Our previous
microdialysis study showed that OSU6162 blunts alcohol-
induced dopamine output in the nucleus accumbens of
alcohol-naïve rats (Steensland et al., 2012), indicating that
OSU6162 might have the potential to attenuate the rewarding
properties of alcohol. This suggestion is supported by our
present ﬁndings that OSU6162 attenuated the “liking” of the
consumed alcohol. However, our more recent microdialysis
study in long-term drinking rats (Feltmann et al., 2015),
indicates that OSU6162 rather might have the ability to
counteract the hypo-dopaminergic state in the striatum
associated with alcohol dependence (Narendran et al.,
2014; Tupala et al., 2001; Volkow et al., 2007, 1996). The
different effects of OSU6162 treatment on the dopamine
output in response to an alcohol-challenge in alcohol-naïve
(Steensland et al., 2012) vs long-term drinking rats with an
established hypo-dopaminergic state (Feltmann et al., 2015),
highlights OSU6162’s ability to stimulate or attenuate dopa-
mine depending on the prevailing tone. OSU6162’s ability to
stabilize dopamine activity is further supported by a PETstudy
in Rhesus monkeys (Tedroff et al., 1998). Although, OSU6162’s
stabilizing ability remains to be shown in humans, it is
tempting to speculate that an OSU6162-induced normaliza-
tion of an dopamine deﬁciency could possibly explain the
present results showing that OSU6162 blunted priming-
induced alcohol craving in dependent individuals, as dopa-
mine deﬁciency has been suggested to drive craving and
contribute to relapse (Koob, 2013).
In the present study we found that OSU6162’s ability to
blunt priming-induced alcohol craving was found only in
individuals with high baseline level of impulsivity. A neurobio-
logical overlap between impulsivity and alcohol dependence
has been suggested (Dick et al., 2010; Lejuez et al., 2010) and
cortical dopamine deﬁcits potentially related to long-term
alcohol use, contributes to impaired impulse control in alcohol
dependent individuals (Goldstein and Volkow, 2011; Stavro
et al., 2013). Furthermore, the ﬁnding that both impulsivity
trait and impaired response inhibition predict higher cue-
induced alcohol craving (Papachristou et al., 2013) is sup-
ported by the present study showing that placebo-treated high
impulsive participants, had a consistently higher rating of their
baseline subjective craving (i.e. before being subjected to thecue- or priming-exposures), than the low impulsive. Thus,
given the role of dopamine in regulating impulsive behavior
and OSU6162’s unique pharmacological proﬁle to regulate the
dopamine activity based on the prevailing dopaminergic tone
(Carlsson et al., 2004; Sonesson et al., 1994; Tedroff et al.,
1998), it is possible that OSU6162’s more beneﬁcial effects on
craving in the high impulsive alcohol dependent individuals is
explained by the function of a potential hypodopaminergic
state in this speciﬁc group on individuals. This hypothesis is
further supported by the ﬁndings that the OSU6162-treated
high impulsive participants had a signiﬁcantly lower rating of
subjective craving compared to the placebo-treated also at
baseline, i.e. before the start of the priming-session. The
present results further suggest that alcohol dependent indivi-
duals with low dopamine levels are likely to experience
greater impairments in impulse control and thus are more
likely to beneﬁt from a dopaminergic agent such as OSU6162.
Although, the ability of OSU6162 to affect impulsivity per se
needs to be investigated, previous studies show that modaﬁnil
improves neuropsychological task performance including stop
signal reaction time task in health volunteers (Turner et al.,
2003) as well as response inhibition (Schmaal et al., 2013), and
prolonging time to relapse (Joos et al., 2013) in alcohol
dependent individuals with high, but not low, baseline impul-
sivity (SSRT). Collectively, these results highlight the potential
beneﬁts of targeting the dopamine system in relation to
impulsive behavior as well as indicate that impulsivity repre-
sents a clinically important phenotype in alcohol dependence,
and needs to be taken into account when evaluating dopami-
nergic agents in this patient population.
Although, the present exploratory human laboratory study
with a 14-day-treatment period was not designed to detect
OSU6162’s effect on alcohol consumption, both OSU6162 and
placebo treatment induced more than 50% reduction in heavy
drinking days. The lack of signiﬁcant differences between the
OSU6162 and placebo groups is most likely attributed to the
fact that participation in a research study per se has beneﬁcial
effects on the alcohol use (Weiss et al., 2008) and that a
treatment period of at least three to six months is required to
reliably establish the efﬁcacy and verify the absence of drug
tolerance of potential medications (European Medicines
Agency, 2010). Indeed recent ﬁndings in patients with mental
fatigue indicate the treatment effect of OSU6162 is slowly
titrated up during the initial weeks of treatment and does not
reach a maximal effect until after several weeks of treatment
(unpublished ﬁndings from co-author Dr Carlsson). Neverthe-
less, in line with previous studies in other patient populations
(Johansson et al., 2012; Kloberg et al., 2014; Tedroff et al.,
1999) OSU6162 treatment was generally well tolerated and
none of the participants dropped out of the study because of
intolerable side effects. Thus, the present beneﬁcial ﬁndings
of safety and effects on alcohol craving render support for a
larger placebo-controlled efﬁcacy clinical trial to evaluate
OSU6162’s effect on drinking outcomes.
In summary, this early Phase II human laboratory study in
alcohol dependent individuals shows that the monoamine
stabilizer OSU6162 was safe and well tolerated and
attenuates priming-induced alcohol craving as well as
liking, in a controlled laboratory environment. OSU6162’s
effects were driven by individuals with high baseline levels
of impulsivity, highlighting the importance of phenotyping
baseline impulsivity when evaluating dopaminergic agents
2249Effects of OSU6162 on Craving for Alcoholin alcohol dependent individuals. A larger placebo-
controlled efﬁcacy clinical trial is needed to further
investigate the potential of OSU6162 as a novel medication
for alcohol dependence.
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